Hiroshi Kondo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroshi Kondo has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Ilaria Gritti
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, USA; Department of Medicine, Harvard Medical School, Boston, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, USA
16 shared publications - Nabeel Bardeesy
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts
16 shared publications - Qin Xu
State Key Laboratory of Epigenetic Regulation and Intervention, Shanghai Key Laboratory of Molecular Andrology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
16 shared publications - Haley Ellis
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, USA; Mass General Brigham Cancer Institute, Boston, USA; Department of Medicine, Harvard Medical School, Boston, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, USA
15 shared publications - James M. Cleary
Dana-Farber Cancer Institute 1 , Boston, Massachusetts
15 shared publications - Jinkai Wan
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, USA; Department of Medicine, Harvard Medical School, Boston, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, USA
15 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Fig. S1, S2, S3, S4, S5 from MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response
Supplementary Figures S1, S2, S3, S4, S5 with legends
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFig. S1, S2, S3, S4, S5 from MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response
Supplementary Figures S1, S2, S3, S4, S5 with legends
- Open Access
- 29 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (5) , 925-937
MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response
Purpose: Mutant IDH1 (mIDH1) defines a therapeutically targetable subtype of intrahepatic cholangiocarcinoma (ICC), with the mIDH1 inhibitor ivosidenib approved for advanced disease. A subset of patients experiences prolonged disease stabilization; however, the molecular basis for eventual progression remains poorly defined. Experimental Design: We performed molecular profiling of matched baseline and postprogression circulating tumor DNA (ctDNA) samples from patients with mIDH1 ICC enrolled in the ClarIDHy phase III trial. Functional studies were conducted to characterize candidate resistance mechanisms. Results: Longitudinal ctDNA analysis of 18 patients treated with ivosidenib for >6 months revealed emergent genomic alterations in multiple cases. Acquired mutations in mitogen-activated protein kinase (MAPK) pathway genes (KRAS, NRAS, MAP2K1, NF1) were identified in five cases, with instances of concurrent alterations and/or high variant allele fractions (VAF). Additional candidate resistance events included a secondary IDH1 mutation and a hotspot IDH2 mutation, detected at low VAF in the same patient. Functional studies showed that these IDH mutations conferred sustained 2-hydroxyglutarate production and ivosidenib resistance, whereas MAPK activation blunted gene expression induced by ivosidenib plus IFNγ, a key therapeutic output of mIDH1 inhibition. In parallel, baseline ctDNA profiling of 81 patients revealed that ARID1A mutations and elevated mIDH1 VAF were associated with reduced clinical benefit. Conclusions: MAPK pathway alterations represent a recurrent mechanism of resistance to mIDH1 inhibition in ICC, whereas emergent IDH1/IDH2 mutations appear infrequent. Functional data suggest that MAPK-mediated resistance may involve impaired IFN signaling. These results support MAPK-directed combination strategies and highlight the utility of ctDNA profiling to identify predictive and resistance biomarkers in mIDH1-driven ICC.
- 29 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (5) , 925-937
Open AccessMAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response
Purpose: Mutant IDH1 (mIDH1) defines a therapeutically targetable subtype of intrahepatic cholangiocarcinoma (ICC), with the mIDH1 inhibitor ivosidenib approved for advanced disease. A subset of patients experiences prolonged disease stabilization; however, the molecular basis for eventual progression remains poorly defined. Experimental Design: We performed molecular profiling of matched baseline and postprogression circulating tumor DNA (ctDNA) samples from patients with mIDH1 ICC enrolled in the ClarIDHy phase III trial. Functional studies were conducted to characterize candidate resistance mechanisms. Results: Longitudinal ctDNA analysis of 18 patients treated with ivosidenib for >6 months revealed emergent genomic alterations in multiple cases. Acquired mutations in mitogen-activated protein kinase (MAPK) pathway genes (KRAS, NRAS, MAP2K1, NF1) were identified in five cases, with instances of concurrent alterations and/or high variant allele fractions (VAF). Additional candidate resistance events included a secondary IDH1 mutation and a hotspot IDH2 mutation, detected at low VAF in the same patient. Functional studies showed that these IDH mutations conferred sustained 2-hydroxyglutarate production and ivosidenib resistance, whereas MAPK activation blunted gene expression induced by ivosidenib plus IFNγ, a key therapeutic output of mIDH1 inhibition. In parallel, baseline ctDNA profiling of 81 patients revealed that ARID1A mutations and elevated mIDH1 VAF were associated with reduced clinical benefit. Conclusions: MAPK pathway alterations represent a recurrent mechanism of resistance to mIDH1 inhibition in ICC, whereas emergent IDH1/IDH2 mutations appear infrequent. Functional data suggest that MAPK-mediated resistance may involve impaired IFN signaling. These results support MAPK-directed combination strategies and highlight the utility of ctDNA profiling to identify predictive and resistance biomarkers in mIDH1-driven ICC.
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 1
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 1
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 7
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 7
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 5
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 5
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 3
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 3
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 6
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 6
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 2
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 2
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S9 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Supplementary Figures associated with each Main Figure
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S9 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Supplementary Figures associated with each Main Figure